PLUS THERAPEUTICS, INC.

Plus Therapeutics, Inc. announced it will host a business update conference call and webcast on June 30, 2026, at 8:30 a.m. ET. Management will provide updates on the CNSide® diagnostic launch, the integrated development plan for its lead drug Reyobiq, and its CNS oncology strategy. The call will also cover the company's native artificial intelligence development plans, with the CEO expressing excitement about progress across all three areas.

Plus Therapeutics, Inc. has entered into an Equity Distribution Agreement with Canaccord Genuity LLC, enabling the company to sell up to $17,350,000 of its common stock. The shares will be offered "at the market" on the Nasdaq Capital Market, with the agent receiving a 3.0% commission. The net proceeds from this offering are intended to be used for general corporate purposes and working capital.

Plus Therapeutics, Inc. announced that its wholly owned subsidiary, CNSide Diagnostics, LLC, has received accreditation from the College of American Pathologists (CAP). This accreditation, recognized as the "gold standard" in laboratory accreditation, follows a rigorous on-site inspection of CNSide Diagnostics' Houston-based clinical laboratory. The company expects this milestone to reinforce clinical confidence, advance payer engagement for broader coverage and reimbursement, facilitate health system adoption, and enable future menu expansion for its CNSide® CSF Assay Platform.

Plus Therapeutics announced a health economics study, co-authored with Harvard, demonstrating that its CNSide cerebrospinal fluid assay can reduce overall leptomeningeal metastases (LM)-related healthcare costs by approximately 33-47%, averaging 40%. This reduction is attributed to earlier therapeutic intervention, improved treatment precision, and fewer hospitalizations. The findings, presented at the ISPOR 2026 Annual Meeting and receiving blue-ribbon recognition, validate CNSide's value for payers and support its commercialization in the US.

Plus Therapeutics announced a strategic partnership with Ephemeral Technologies to create a unique AI execution platform for central nervous system (CNS) oncology. This platform will integrate and analyze Plus' proprietary therapeutic, diagnostic, and bioinformatics datasets to accelerate precision neuro-oncology. The collaboration aims to enhance operational efficiency in both laboratory and clinical settings, with further AI integration planned for future workflows and patient stratification.

PLUS THERAPEUTICS, INC. reported a significantly reduced net loss of $(6.95) million for the first quarter of 2026, compared to $(17.40) million in the prior year, largely due to lower other expenses. The company also announced it has regained compliance with the Nasdaq Minimum Bid Requirement following a 1-for-25 reverse stock split. Despite these improvements, operating expenses increased, and the company continues to face a 'going concern' warning due to its ongoing need for additional financing.

Plus Therapeutics reported a net loss of $(6.9) million, or $(1.05) per basic share, for Q1 2026, compared to a net loss of $(17.4) million, or $(29.86) per basic share, in Q1 2025. The company's cash and investments balance increased to $15.1 million as of March 31, 2026, following a $15 million public offering. Key business updates include FDA Orphan Drug Designation for REYOBIQ, expanded payer coverage for CNSide to 81 million lives, and progress on clinical trials and commercial readiness.

Plus Therapeutics reported Q1 2026 financial results, including $1.0 million in revenue and a net loss of $6.9 million. The company significantly strengthened its financial position with a $15 million public offering, increasing cash and investments to $15.1 million. Key business highlights include receiving U.S. FDA Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas, securing a CPT reimbursement code for REYOBIQ, and expanding CNSide payer coverage to approximately 81 million lives. The company reaffirmed its 2026 milestones, focusing on CNSide commercial scale-up and REYOBIQ pivotal-trial readiness.

Plus Therapeutics announced the presentation of positive Phase 1 ReSPECT-LM trial data for REYOBIQ ™ (rhenium Re186 obisbemeda) at the 2026 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting. The data highlighted encouraging survival outcomes, robust anti-tumor activity, and a favorable safety profile for patients with leptomeningeal metastases. Patients treated at the recommended Phase 2 dose achieved a median overall survival of approximately 9 months, significantly exceeding historical survival rates of 2-6 months. Translational analyses also indicated potential immune remodeling, supporting future combination strategies, and the multiple-dose trial is currently enrolling patients.

Plus Therapeutics' wholly owned subsidiary, CNSide Diagnostics, has successfully enrolled in the Medicare program and received a Provider Transaction Access Number (PTAN) from CMS. This critical milestone establishes CNSide Diagnostics as a Medicare-enrolled clinical laboratory, enabling the submission of claims for its CNSide® Cerebrospinal Fluid (CSF) Assay Platform, including the tumor cell enumeration (TCE) test. The enrollment expands patient access to approximately half of the U.S. Medicare population, building on the existing 81 million commercial covered lives, with a goal of achieving over 150 million covered lives by 2026. This move is a key step in the commercialization strategy, facilitating billing for Traditional Medicare and paving the way for expansion into Medicare Advantage and Medicaid populations.